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particular clinical importance, we found that strict glycaemic control was associated with an increased risk of death among individuals with long (≥ 5 years) diabetes duration. Conversely, for individuals with short diabetes duration, strict glycaemic control was associated with the lowest risk of death. These results indicate that tight glycemic control may be beneficial in people with short duration of diabetes, whereas a less stringent target may be warranted with longer diabetes exposure.
death, elderly, hypoglycaemia, optimal glycaemic target, overtreatment, type 2 diabetes, variability 1 | INTRODUCTION Up to one in four older adults (≥ 65 years) have type 2 diabetes (T2D), 1 and with the overall aging of the population, this number is likely to increase. 2 Compared with older individuals without diabetes, those with T2D are at increased risk of premature death, 3 functional disabilities, 4 hypertension, 5 coronary heart disease, 6 stroke, 6 and other geriatric comorbidities, including cognitive impairment, 7 depression, 8 falls, 9 polypharmacy 10 and hypoglycaemia. 11 Despite the considerable burden of T2D in older adults, little is known about the specific risks and benefits associated with glycated haemoglobin (HbA1c) targets in older adults. This lack of evidence is partly attributable to the historical exclusion of older adults from clinical trials. 12 The UK Prospective Diabetes Study selectively excluded patients aged >65 years. 13 Although subsequent major clinical trials included individuals aged >65 years, the number of individuals aged >75 years at the time of enrolment was limited. [14] [15] [16] Moreover, there is a considerable heterogeneity in overall health status within the elderly, making it difficult to develop "one-size-fits-all" standards for the growing older community. Thus, clinical decision-making in older adults relies heavily on expert opinion and extrapolation of evidence from clinical trials of younger and healthier patients. 17 Guidelines on diabetes care from multiple clinical organizations have all adopted the concepts of individualized glycaemic targets and care management by weighing treatment benefits against age, life expectancy, burden of comorbidity, functional and cognitive impairment. Although guidelines agree on individualization, they differ in the details of their recommendations, in terms of patient categories and glycaemic targets. [18] [19] [20] [21] [22] [23] Using a large contemporary primary care cohort of older adults with T2D, we aimed to investigate the effect of diabetes duration on glycaemic control and mortality risk, within different age, sex and clinically relevant comorbidity-defined subgroups.
| METHODS

| Study population
Until 2015, general practitioners working in the Copenhagen municipality and the former Copenhagen county referred their patients for blood sampling at one core facility (the Copenhagen General Practitioner's Laboratory; CGPL). From the CGPL, we identified all patients with T2D aged ≥65 years, who had three annual HbA1c measurements taken between 1 January 2005 and 31 December 2013. Individuals were included if they, in addition to the first HbA1c measurement, had two consecutive annual measurements of HbA1c, one after 1 year (±4 months) and another after 2 years (± 4 months).
The baseline date for follow-up was set at the third measurement of HbA1c. For each individual, we defined our primary exposure as the mean HbA1c of the three measurements ( Figure S1 ). A flowchart of study inclusion and exclusion criteria is provided in Figure S2 . Individuals were categorized into clinically relevant mean HbA1c groups of <6.5% (<48 mmol/mol), 6.5%-6.9% (48 to 52 mmol/mol), 7%-7.9% (53 to 63 mmol/mol), 8%-8.9% (64 to 74 mmol/mol) and ≥9% (≥75 mmol/mol). 
| HbA1c assays
| Data sources
Citizens with a permanent address in Denmark are assigned a unique civil registration number, which allows linkage on an individual-level to nationwide administrative registries. The National Population Registry contains information on sex, date of birth, date of emigration and date of death. 25 The Danish National Patient Registry holds information on all hospitalizations, outpatient clinic and emergency room admissions. 26 When patients are discharged from the hospitals, contacts are registered with a primary discharge diagnosis, and subsequently classified according to the 10th revision of the International Classification of Disease (ICD-10). The Danish National Prescription Registry contains individual-level records on dispensing date, strength, quantity and drug type (using the Anatomical Therapeutic Chemical System), on all claimed drug prescriptions dispensed from pharmacies in Denmark. 27 Using these registries, we attained information on comorbidity, concomitant drug therapy, and outcomes. The cause of death, classified using ICD-10 codes, was extracted from the Danish Register of Causes of Death. 28 In accordance with Danish law, no approval from an ethics committee was needed in this registry-based study with no active participation from study subjects. The use of deidentified registry data was approved by the Danish Data Protection Agency (record number 2007-58-0015).
| Baseline variables and endpoints
Using the aforementioned nationwide administrative registries, we identified individuals with T2D, defined by a registry diagnosis of T2D and/or redeemed prescription of an oral antidiabetic drug or insulin. This definition has previously been shown to have a positive predictive value of 97%. 29 Individuals with a registry diagnosis of type 1 diabetes were excluded. For each individual, the following comorbidities were identified by discharge diagnoses prior to baseline: macrovascular disease, microvascular disease, atrial fibrillation, hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), depression, dementia, cancer without metastases, cancer with metastases, arthritis, urinary incontinence, falls, treatment with dialysis, alcoholrelated contacts, as well as a registry diagnosis for obesity. 30 Renal impairment was categorized as: stages 1 and 2: eGFR ≥ 60 mL/min/1.73 m 2 ; stage 3A: eGFR 45 to 59 mL/min/1.73 m 2 ; stage 3B: eGFR 30 to 44 mL/min/1.73 m 2 ; and stages 4 and 5: eGFR ≤29 mL/min/1.73 m 2 . Fall traumas needing medical assistance was used as a proxy for frailty, and defined as discharge diagnoses of contusions or fractures of the head, upper or lower extremities within 5 years prior to baseline. Diabetes duration was categorized into levels of short (<5 years) and long (≥ 5 years) duration.
Diagnoses and procedure codes are listed in Table S1 . Use of pharmacotherapy was defined as one or more claimed prescribed drugs within 6 months prior to baseline. Individuals with multiple prescriptions (polypharmacy) were categorized into three groups (0-3, 4-5, ≥6 prescribed drugs). Treatment with the following drugs was assessed: antidiabetic medication; anti-hypertensive medications; antithrombotic medications; oral anticoagulant therapy; and statins. A detailed description of codes used to define concomitant pharmacological treatment is listed in Table S2 . We defined hypertension as a registry diagnosis of hypertension or concomitant treatment with two or more types of antihypertensive drugs, as done previously. 31 The primary endpoint of interest was death from any cause. Secondary endpoints were death from cardiovascular disease and non-cardiovascular disease.
| Classification of comorbidity burden
In the most recent American Diabetes Association (ADA) and American Geriatric Society (AGS) guidelines, individual glycaemic targets are advised according to the number and severity of specific medical complexities listed in the guidelines. 18 By adopting the ADA/AGS guidelines, we constructed a modified ADA/AGS three-tier comorbidity classification. 18 Individuals were classified as "healthy", if they had at most two of the chronic comorbidities listed in Table S3 , as having "moderate" comorbidity if they had three to five chronic comorbidities, and lastly, as having "severe" comorbidity, if they had at least six chronic comorbidities and/or had metastatic cancer disease, dementia and/or chronic kidney disease requiring dialysis, as described in the ADA/AGS guidelines. 18 We did not have data on staging with respect to heart failure and pulmonary disease, or data on functional status.
| Statistical analyses
Baseline characteristics of the study cohort were expressed as number (proportion), mean (SD) or median (interquartile range [IQR]), where appropriate. We used multiple Cox regression to study the effect of glycaemic control on the hazard of all-cause and cause-specific mortality. Three different models were used to calculate the hazard ratios (HRs). In model 1, we adjusted for baseline age group (65-70 years, 70-75 years and >75 years) and sex. In model 2, we additionally adjusted for prevalent comorbidity (macrovascular disease, microvascular disease, atrial fibrillation, hypertension, congestive heart failure, COPD, depression, dementia, arthritis, urinary incontinence, falls, treatment with dialysis, cancer with and without metastases, alcohol-related diagnoses and obesity) and calendar year at baseline (third measurement), to account for changes in healthcare delivery over time. Model 3 represented the fully adjusted model, where we additionally adjusted for concomitant medication (antithrombotic medication, anticoagulant therapy, lipid-lowering medication, antidiabetic medication). Use of antidiabetic medication was analysed as independent variables: metformin, sulphonylureas and insulin (treatment vs. no treatment). Treatment with α-glucosidase inhibitors, thiazolidinediones and newer drug classes, such as incretin drugs and selective glucose reuptake inhibitors, were categorized as one group, as the drug exposure for these drugs was negligible during the study period (Table S2 ). The mean HbA1c category with the lowest hazard was selected as reference. Time zero for all time-to-event analyses was the date of third HbA1c measurement (baseline). Individual follow-up ended in case of death, emigration from Denmark, or at 31 December 2015, whichever occurred first. We also constructed a risk chart, displaying the 5-year absolute risks of allcause mortality for different combinations of age groups, sex and medical complexities, by mean HbA1c categories. Risk charts were separately reported for short and long diabetes duration and predicted using Cox regression.
| Sensitivity analyses
To test the robustness of our results, we conducted a number of sensitivity analyses. First, to evaluate the functional relationship between mean HbA1c and diabetes duration, we constructed a twodimensional contour plot, based on restricted cubic splines using Cox regression. We modelled an interaction term between mean HbA1c and diabetes duration, considering both as continuous variables instead of categories. Knots were set at the 5th, 50th and 95th percentiles. Second, to test whether any association was dependent on the number of measurements, we conducted additional analyses using one or two (±4 months) annual measurements only, respectively. Third, to test whether a more strict or liberal time-related inclusion yielded similar results, we included individuals with three HbA1c measurements, annually spaced ±3 and ± 5 months, respectively. Fourth, as an alternate measure for glycaemic control, we tested whether the use of the last HbA1c (third measurement) instead of the mean HbA1c yielded comparable results. Fifth, to further explore whether any association with mortality could be confounded by hypoglycaemia, we adjusted the main model for hypoglycaemic events prior to baseline. Last, recent evidence suggests that variability, that is, glycaemic fluctuations over time, provides additional prognostic information, independent of glycaemic control, with regard to mortality in patients with T2D. 32, 33 To address the effect of variability on the association between mean HbA1c and mortality risk, we adjusted the main models for HbA1c variability. Variability was defined as the standard deviation of the residuals, obtained using linear regression on the three measurements, as has been done previously ( Figure S1 ). 31 Variability was categorized into tertiles (low, moderate and high variability). We also accounted for the overall trend in HbA1c by adjusting for the slope (beta) estimate, which was also categorized into tertiles (decreasing, stable and increasing trend).
Potential effect modifications between mean HbA1c levels and outcome hazard rates by age groups, sex, diabetes duration and comorbidity burden, were evaluated using likelihood ratio tests comparing the main model to a model containing the interaction term. A two-sided P value <.05 was taken to indicate statistical significance. Figure 1A , model 1). The point estimates were slightly attenuated, when we adjusted for disease-and age-related comorbidity and concomitant medication. However, we observed a similar dose-response relationship, with the highest hazard for allcause mortality associated with mean HbA1c levels of 8.0%-8.9%
(64 to 74 mmol/mol; HR 1.50, 95% CI 1.18-1.90, P < .001[ Figure 1A , model 3]). We also calculated 5-year absolute risks of all-cause mortality ( Figure 2) , and found that the risk of all-cause mortality increased with increasing levels of HbA1c, irrespective of age, sex and comorbidity strata. When evaluating the relationship between levels of glycaemia and diabetes duration as continuous variables, we found that the hazard of death increased with increasing levels of glycaemia for individuals with shorter diabetes duration (Figure 3) . A similar pattern of association with overall higher point estimates was observed for non-cardiovascular deaths. For cardiovascular deaths, the direction of effect was similar to the main model, albeit with none of the associations reaching statistical significance (Figure 4 ). We found no effect modification with respect to age, sex or comorbidity (P for interaction >.05). with the lowest hazard of all-cause mortality was 6.5%-7.9% (48 to 63 mmol/mol). For non-cardiovascular mortality, the pattern of association was similar to that for all-cause mortality. We found no significant association with cardiovascular death (Figure 4 ), albeit the point estimates tracked in the same direction. The lowest 5-year absolute risk of death was also associated with mean HbA1c levels between 6.5%-7.9% (48 and 63 mmol/mol), irrespective of the degree of comorbidity or sex and age group, with increased risks at both low and high levels of glycaemia ( Figure 2 ). With increasing duration of diabetes, the hazard of all-cause mortality shifted from a linear, towards a non-linear pattern, with the highest hazard among individuals very long diabetes duration and low levels of glycaemia ( Figure 3 ). We found no effect modification with respect to age, sex or comorbidity (P for interaction >.05). Note: Due to Danish data protection regulation (the Act on Processing of Personal Data), any observations <4 may not be reported. Diagnoses of obesity and alcohol were obtained from registry diagnoses. Abbreviations: ADA, American Diabetes Association; AGS, American Geriatric Society; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; n, number of individuals; OAD, oral antidiabetic drug; RAS, renin-angiotensin system.
| Glycaemic control by degree of comorbidity
To evaluate glycaemic control levels among older adults with T2D by overall health status, we categorized individuals based on the number and severity of comorbidities (Table S4 ). Overall, we found that 70.7% and 69.5% of patients with moderate and severe comorbidity, respectively, had glycaemic levels 7% (<53 mmol/mol). We also found that individuals with moderate and severe comorbidity were generally older, had longer diabetes duration, and were more often treated with multiple drugs, in particular sulphonylureas and insulin, compared with individuals classified as healthy ( 
| Sensitivity analyses
To test the robustness and generalizability of our associations, we conducted seven sensitivity analyses. The results did not materially change when modelling the exposure as a continuous variable ( Figure 3) . Nor did the pattern of association change when using a different number of measurements, different time-related cut-offs for inclusion, an alternate exposure of HbA1c (last measurement instead of mean HbA1c) or adjusting the main model for hypoglycaemic events, HbA1c variability or trend ( Figure S3 ). Moreover, we found that the hazard of death increased monotonically with increasing HbA1c variability for individuals with short duration of diabetes, but not for individuals with longstanding diabetes.
Also, increasing trend compared with a stable trend in HbA1c was associated with increased hazard of death in both individuals with short and long duration of diabetes. However, a decreasing trend was only associated with increased hazard in individuals with longstanding disease.
F I G U R E 1 Glycated haemoglobin (HbA1c) categories and the hazard ratio (HR) of all-cause mortality by groups of A, short (<5 years) and B, long (≥5 years) diabetes duration. Model 1 was adjusted for age groups (65-70 years, 70-75 years and > 75 years) and sex. Model 2 was additionally adjusted for comorbidity (macrovascular disease, microvascular disease, atrial fibrillation, hypertension, congestive heart failure, chronic obstructive pulmonary disease, depression, dementia, cancer, arthritis, urinary incontinence, falls, treatment with dialysis, cancer with metastases, alcohol-related diagnoses, and obesity) and calendar period. Model 3 represented the fully adjusted model, where we additionally adjusted for concomitant medication (antithrombotic medication, anticoagulant therapy, lipid-lowering medication, and antidiabetic medication). The solid dots refer to the HR's, and horizontal lines represent 95% confidence intervals (CI). The HbA1c category with the lowest hazard was selected as reference
| DISCUSSION
Using real-world data of older primary care patients with T2D, we found that the association between glycaemic control and the risk of death depended on the duration of diabetes. For individuals with short diabetes duration (<5 years), we found that the risk of death increased with poorer glycaemic control, whereas for individuals with longstanding diabetes (≥5 years), we found a J-shaped association,
Five-year absolute risk prediction chart for all-cause mortality, based on individuals with A, short (<5 years) and B, long (≥5 years) diabetes duration, and the combination of age groups, sex and comorbidity, with respect to different levels of mean glycated haemoglobin (HbA1c, in %). Individuals were classified as healthy, if they had ≤2 comorbidities, moderate if they had three to five comorbidities, and severe, if they had ≥6 comorbidities and/or had metastatic cancer disease, dementia, or chronic kidney disease requiring dialysis. The colour scheme refers to the absolute 5-year risk (%) for all-cause mortality F I G U R E 3 Contour plot displaying the functional relationship between levels of mean glycated haemoglobin (HbA1c; mmol/mol and %) and diabetes duration (years), using restricted cubic splines regression. Knots were set at the fifth, 50th and 95th percentile. A mean HbA1c value of 6.5% (48 mmol/mol) and diabetes duration of 2 years was set as reference. Only data between the 10th and 90th percentile is shown, to avoid presenting results for mean HbA1c and diabetes duration values for which the number of observations were small. The solid lines and the colour scheme refer to the hazard ratio (HR) for all-cause mortality. The model was adjusted as described in Figure 1 (model 3) with the lowest risk associated with glycaemic levels between 6.5%-7.9% (48 and 63 mmol/mol). These results were consistent across different age, sex and comorbidity-defined subgroups.
Previous studies on middle-aged patients with T2D have shown conflicting results concerning the relationship between glycaemic control, diabetes duration and mortality risk. For instance, in a recent study by Laiteerapong et al. 34 the authors found that newly diagnosed middle-aged patients with tight glycaemic control (6.5% [<48 mmol/mol ]) had the lowest mortality risk, with increasing effect sizes with longer exposure to poor glycaemic control. 34 As opposed to our results on elderly patients, they found no increased mortality risk in the normoglycaemic range with increasing duration of diabetes. In another, smaller study (531 individuals) of middle-aged patients with T2D, it was found that long diabetes duration (≥5 years) and good glycaemic control (<6.5% [48 mmol/mol]) was associated with increased risk of death. However, no incremental risk was observed in patients with a combination of longstanding diabetes and higher levels of glycaemia. 35 Lastly, a duration-dependent relationship has also been reported for cardiovascular events in a post hoc analysis of the Veterans Affairs Diabetes Trial, where patients in the intensive arm, who entered the trial with a diabetes duration >15 years, had a higher risk of macrovascular events, compared with the standard arm. 31 We are, to the best of our knowledge, the first to extend this durationdependent relationship between glycaemic control and mortality risk to an elderly population with T2D. We are also the first to report that significant risk exists in both the higher and lower tails of glycaemia in elderly patients with longer diabetes exposure.
The interaction between diabetes duration and glycaemic control on the risk of death that we report could potentially also explain the inconsistencies between previous observational studies on older patients with T2D, which have reported both linear 32, 33 and nonlinear relationships 30, 34, 35 between levels of glycaemia and mortality risk. Although the present study does not allow for causal inference due to its observational design, our results suggest that aiming for normoglycaemic levels in those with short duration of diabetes may be beneficial, whereas for individuals with long diabetes duration, setting universal goals may be less straightforward. In these patients, Hypoglycaemia is a potent candidate mechanism. We found that individuals with longstanding diabetes were more often prescribed sulphonylureas and insulin compared with individuals with short diabetes duration (Table 1 and Tables S5 and S6 ). These drugs can by themselves, or in concert with malnourishment, severe comorbidity, cognitive impairment and/or polypharmacy, induce hypoglycaemia, all of which were more prevalent in the long diabetes duration group.
Hypoglycaemia, in particular in the elderly, is important to prevent, as it is associated with falls, cognitive impairment, hospitalizations, cardiovascular events and mortality risk. 18, [36] [37] [38] Also, low levels of glycaemia may not always be indicative of intentional good glycaemic control, but rather a proxy for poor nutritional status and general frailty, both of which have been associated with increased mortality risk. 39 The latter is supported by the existence of a J-shaped association between levels of glycaemia and mortality risk in non-diabetic populations, suggesting that non-glycaemic factors may partly explain the observed risk in the lower glycaemic range. 40 In terms of glycaemic variability, our results are in accordance with previous studies that have shown that higher variability in HbA1c is associated with an increased risk of mortality in patients with T2D. 33, 41 However, the present study provides additional evidence that, at least in older adults, the prognostic effect of HbA1c variability may be specific to patients with short duration of diabetes, but not long duration. By contrast, a decreasing trend in HbA1c in the present study was associated with increased risk of death in patients with long diabetes duration, but not in those with short duration. From a clinical standpoint, variability might represent an important prognostic marker in patients with short duration of diabetes, whereas physicians may need to be more attentive not only to low levels of glycaemia, but also unintentional decreasing HbA1c over time, in particular in patients with longstanding diabetes.
In the present study, we also found signs of potential over- [42] [43] [44] We found no evidence of differences in optimal treatment targets across the three comorbidity tiers. However, this does not invalidate differentiated treatment goals by different comorbidity strata, as advised by current clinical recommendations. For healthy older people, with short diabetes duration and extended life expectancy, a glycaemic target similar to that for younger patients (7% [<53 mmol/ mol]) may be appropriate. In accordance with our data, tight glycaemic control may also be appropriate in patients with several comorbidities Moreover, we used serial HbA1c, allowing a more detailed evaluation of long-term glycaemic control, as well as being able to account for the effect of temporal fluctuations in HbA1c.
Some limitations of this study should also be noted. We did not have information on functional limitations, for example, activities of daily living; however, our data were collected from available laboratory records as part of the patient's routine clinical follow-up, suggesting that our results are most likely based on patients with a certain degree of self-management and preserved functional abilities.
We did not have information on the indication for HbA1c testing; thus, patients with three annual measurements could, in theory, represent a selected group of patients. We found that individuals with nonannual measurements were slightly older, with longer duration of diabetes, had marginally poorer glycaemic control, more diabetes-related late complications and other major comorbidities (Table S7 ). However, we do not believe that this selection of patients has affected the generalizability of our results, as we found similar results for individuals with one, two and three annual measurements, as well as for individuals with a non-annual referral pattern.
In conclusion, this cohort study of older primary care patients aged ≥65 years with T2D demonstrates that the risk of mortality differs by levels of glycaemia and duration of the disease. For individuals with short diabetes duration (<5 years), we found that the risk of death increased with poorer glycaemic control, whereas for individuals with longstanding diabetes (≥5 years), we found a J-shaped association, with the lowest risk associated with glycaemic levels of 6.5%-7.9% (48 to 63 mmol/mol).
